Yufeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yufeng Li has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Fakuo Gong
Department of Nuclear Medicine, Panzhihua Central Hospital, Sichuan Province, 617067, Panzhihua City, People's Republic of China
1 shared publicationHao Zhang
Department of Thoracic Cardiovascular Surgery, Affiliated Hospital of Xuzhou Medical College, 99 Huaihai Road, Xuzhou, 221006, Jiangsu Province, China
1 shared publication- Hongyan Dong
Research Facility Center for Morphology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China
1 shared publication Huan Wang
Department of Nuclear Medicine, Panzhihua Central Hospital, Sichuan Province, 617067, Panzhihua City, People's Republic of China
1 shared publicationHui Wang
Department of Nuclear Medicine, Panzhihua Central Hospital, Sichuan Province, 617067, Panzhihua City, People's Republic of China
1 shared publicationJiangming Sun
Department of Nuclear Medicine, Panzhihua Central Hospital, Sichuan Province, 617067, Panzhihua City, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 18 November 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 689, 149159
Corrigendum to (title of manuscript): PEDF attenuates hypoxia-induced apoptosis and necrosis in H9c2 cells by inhibiting p53 mitochondrial translocation via PEDF-R
- 18 November 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 689, 149159
Open AccessCorrigendum to (title of manuscript): PEDF attenuates hypoxia-induced apoptosis and necrosis in H9c2 cells by inhibiting p53 mitochondrial translocation via PEDF-R
- Open Access
- 12 November 2019
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 19 (1) , 1-6
Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules
Background: Benign thyroid nodules (BTN) are frequently diagnosed as papillary thyroid carcinoma (PTC), leading to unnecessary treatment. We found that plasma lncRNA DLG1-AS1 was upregulated in PTC patients but not in BTN patients and healthy controls. Methods: In this study DLG1-AS1 and miR-199a-3p in plasma of both PTC patients and BTN patients were detected by qPCR. ROC curve analysis was performed for diagnostic analysis. Overexpression experiments were performed to analyze the interaction between DLG1-AS1 and miR-199a-3p. CCK-8 assay was performed to analyze cell proliferation. Results: In this study, upregulation of DLG1-AS1 distinguished PTC patients from BTN patients and healthy controls. Plasma miR-199a-3p was downregulated in PTC patients compared with healthy controls and BTN patients. Plasma levels of miR-199a-3p were inversely correlated in PTC patients, but not in BTN patients and healthy controls. miR-199a-3p overexpression failed to significantly affect DLG1-AS1, while DLG1-AS1 overexpression resulted in downregulated miR-199a-3p, In addition, DLG1-AS1 overexpression promoted the proliferation of PTC cells. miR-199a-3p overexpression played an opposite role and attenuated the effects of DLG1-AS1 overexpression. Conclusions: Therefore, DLG1-AS1 may promote PTC by downregulating miR-199a-3p.
- 12 November 2019
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 19 (1) , 1-6
Open AccessAltered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules
Background: Benign thyroid nodules (BTN) are frequently diagnosed as papillary thyroid carcinoma (PTC), leading to unnecessary treatment. We found that plasma lncRNA DLG1-AS1 was upregulated in PTC patients but not in BTN patients and healthy controls. Methods: In this study DLG1-AS1 and miR-199a-3p in plasma of both PTC patients and BTN patients were detected by qPCR. ROC curve analysis was performed for diagnostic analysis. Overexpression experiments were performed to analyze the interaction between DLG1-AS1 and miR-199a-3p. CCK-8 assay was performed to analyze cell proliferation. Results: In this study, upregulation of DLG1-AS1 distinguished PTC patients from BTN patients and healthy controls. Plasma miR-199a-3p was downregulated in PTC patients compared with healthy controls and BTN patients. Plasma levels of miR-199a-3p were inversely correlated in PTC patients, but not in BTN patients and healthy controls. miR-199a-3p overexpression failed to significantly affect DLG1-AS1, while DLG1-AS1 overexpression resulted in downregulated miR-199a-3p, In addition, DLG1-AS1 overexpression promoted the proliferation of PTC cells. miR-199a-3p overexpression played an opposite role and attenuated the effects of DLG1-AS1 overexpression. Conclusions: Therefore, DLG1-AS1 may promote PTC by downregulating miR-199a-3p.